• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.

作者信息

Przepiorka D, Thomas E D

机构信息

Fred Hutchinson Cancer Research Center, Seattle, Washington.

出版信息

Bone Marrow Transplant. 1988 Mar;3(2):113-9.

PMID:3048475
Abstract

The cytogenetic data for 126 patients with Ph-positive chronic myelogenous leukemia (CML) in accelerated phase or blast crisis were analysed for clonal chromosomal abnormalities in addition to the standard Ph prior to allogeneic or syngeneic bone marrow transplantation (BMT). Additional clonal abnormalities were found in 84%, and 14% had a variant Ph (VPh). In decreasing order of frequency, the most common clonal abnormalities were a second Ph, +8, i(17q), -Y and +19. A second Ph, VPh or +8 occurred more frequently in patients who relapsed following BMT than in those who survived disease-free for at least 1 1/2 years. The presence of an i(17q) alone did not correlate with relapse. The patients with a second Ph, VPh or +8 had a median time to relapse of 19 months, and the risk of relapse at 3 years was 73%. Those with other or no additional clonal abnormalities had not reached a median time to relapse and had a 3-year risk of relapse of 31% (p = 0.002). This analysis suggests that specific cytogenetic abnormalities may be useful indicators of resistance to therapy for CML and should be included in proportional hazard models to predict outcome after BMT.

摘要

相似文献

1
Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.
Bone Marrow Transplant. 1988 Mar;3(2):113-9.
2
Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia.
Bone Marrow Transplant. 2000 Jan;25(2):143-6. doi: 10.1038/sj.bmt.1702133.
3
Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612).晚期白血病骨髓移植后细胞遗传学与疾病状态及治疗结果的相关性:西南肿瘤协作组研究(SWOG-8612)
Leuk Res. 1995 Jun;19(6):381-8. doi: 10.1016/0145-2126(94)00162-4.
4
Relapse after allogeneic bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia: cytogenetic analysis of 24 patients.
Bone Marrow Transplant. 1988 Sep;3(5):413-23.
5
Relapse and cytogenetic evolution in myeloid neoplasms.髓系肿瘤的复发和细胞遗传学演变。
Panminerva Med. 2017 Dec;59(4):308-319. doi: 10.23736/S0031-0808.17.03380-8.
6
Serial cytogenetic studies in allografted patients with chronic myeloid leukemia.
Bone Marrow Transplant. 1992 Apr;9(4):263-8.
7
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.细胞遗传学克隆进化在慢性粒细胞白血病中的意义
J Clin Oncol. 1996 Jan;14(1):196-203. doi: 10.1200/JCO.1996.14.1.196.
8
Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan.转化型Ph阳性慢性粒细胞白血病的染色体特征。对台湾23例中国患者的研究。
Cancer Genet Cytogenet. 1989 May;39(1):89-97. doi: 10.1016/0165-4608(89)90234-3.
9
[The morphological, immunophenotypical and cytogenetic characteristics study of blast crisis in chronic myeloid leukemia].[慢性髓性白血病急变期的形态学、免疫表型及细胞遗传学特征研究]
Zhonghua Nei Ke Za Zhi. 2002 Oct;41(10):685-7.
10
Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia.慢性髓性白血病急变期的核型异常及其临床意义
J Mol Med (Berl). 1997 Nov-Dec;75(11-12):836-8. doi: 10.1007/s001090050173.

引用本文的文献

1
Management of Chronic Myeloid Leukemia in Advanced Phase.晚期慢性髓性白血病的管理
Front Oncol. 2019 Oct 25;9:1132. doi: 10.3389/fonc.2019.01132. eCollection 2019.
2
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.二代酪氨酸激酶抑制剂治疗慢性髓性白血病患者克隆进化的生存结果。
Cancer. 2010 Jun 1;116(11):2673-81. doi: 10.1002/cncr.25015.
3
Karyotype abnormalities and their clinical significance in a group of chronic myeloid leukemia patients treated with hematopoietic stem cell transplantation.
一组接受造血干细胞移植治疗的慢性髓性白血病患者的核型异常及其临床意义
Sao Paulo Med J. 2007 Jul 5;125(4):246-9. doi: 10.1590/s1516-31802007000400011.